Cardiol Therapeutics Inc.
TSX:CRDL.TO · Toronto Stock Exchange
+$0.00 today
Vol 0.00M · Avg 0.12M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-189.2%
avg -96.9%
ROIC
-190.6%
avg -96.7%
ROA
-143.2%
avg -79.7%
Analysis
ROA is currently the strongest return metric at -143.2% versus its period average of -79.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Andrew Warwick Hamer | Chief Medical Officer and Head of Research & Development | $801,662.00 | — | 64 | — | — |
David G. Elsley | President, Chief Executive Officer & Director | $774,400.00 | — | — | — | — |
Bernard Lim | Chief Operating Officer | $531,300.00 | — | — | — | — |
Christopher J. Waddick | Chief Financial Officer, Corporate Secretary & Director | $303,600.00 | — | — | — | — |
John A. Geddes BSCPT | Vice President of Corporate Development | — | — | — | — | — |
Trevor Burns | Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +138.5% (9yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +138.5% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Cannara Biotech Inc.
LOVE.V
$181.03M
BioSyent Inc.
RX.V
$160.02M
Grown Rogue International Inc.
GRIN.CN
$149.96M
HLS Therapeutics Inc.
TSX:HLS.TO
$133.86M
Jushi Holdings Inc.
JUSH.CN
$133.80M
Satellos Bioscience Inc.
TSX:MSCL.TO
$125.22M
Zentek Ltd.
ZEN.V
$62.38M
Vext Science, Inc.
VEXT.CN
$61.92M
Planet 13 Holdings Inc.
PLTH.CN
$60.79M
BioNxt Solutions Inc.
BNXT.CN
$48.08M
Who manages CRDL.TO?
Cardiol Therapeutics Inc. (CRDL.TO) lists 6 active executives. The top listed executive is Christopher J. Waddick, Chief Financial Officer, Corporate Secretary & Director.
Explore More
Continue the stock analysis
Jump to another research area for this company.